Trillium Therapeutics, a wholly-owned subsidiary of Stem Cell Therapeutics, has completed dosing in patients with interstitial cystitis / bladder pain syndrome (IC/BPS) in the Phase I study of TTI-1612.
The safety and tolerability of single ascending doses of TTI-1612, a locally-delivered recombinant growth factor, will be assessed in IC/BPS patients during the study.
Go deeper with GlobalData
TTI-1612 is being developed to correct dysfunction and restore the bladder epithelium to a normal, healthy state.
Stem Cell Therapeutics chief scientific officer Dr Bob Uger said the on-time completion of dosing in the study is a significant early milestone in TTI-1612’s development.
“We are encouraged by our clinical experience to date with this drug, and believe we are setting the groundwork for a partner to move this program forward into Phase II testing,” Uger said.
The study, which enrolled a total of 28 patients at four urology clinics in Southern Ontario, has also evaluated pharmacokinetics and changes in disease symptoms.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to preliminary data, the drug exhibited a favourable pharmacokinetic profile and is well-tolerated.
The company expects to release the study results soon.
